Medicare Enrolled

Dr. Alexander Peck, DO

Rheumatology · Los Angeles, CA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
5230 PACIFIC CONCOURSE DR STE 100, Los Angeles, CA 90045
3102979221
In practice since 2017 (9 years)
NPI: 1588197545 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Peck from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Peck? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Peck

Dr. Alexander Peck is a rheumatology specialist in Los Angeles, CA, with 9 years of NPI registration. Based on federal Medicare data, Dr. Peck performed 40,486 Medicare services across 794 unique beneficiaries.

Between the years covered by Open Payments, Dr. Peck received a total of $7,177 from 22 pharmaceutical and/or device companies across 267 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Peck is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 9 years in practice ▲ Top 12% volume in CA $7,177 industry payments

Medicare Practice Summary

Medicare Utilization ↗
40,486
Medicare services
Top 12% in CA for rheumatology
794
Unique beneficiaries
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,498 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Golimumab infusion (Simponi Aria)
Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery.
13,850 $11 $27
Romosozumab injection (Evenity) for osteoporosis 9,660 $8 $14
Denosumab injection (Prolia/Xgeva) 8,700 $18 $30
Abatacept infusion (Orencia)
An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered.
6,400 $32 $85
Infliximab infusion (Remicade)
An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose.
770 $26 $120
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
301 $105 $356
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
211 $116 $406
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
199 $59 $225
Blood draw (venipuncture)
Insertion of a needle into a vein to collect a blood sample.
194 $7 $8
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
92 $12 $41
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
46 $126 $461
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
32 $50 $200
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
31 $62 $253
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
52.5% high complexity
46.1% medium
1.4% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$7,177
Total received (2022-2024)
Avg $2,392/year across 3 years
Top 35% in CA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
22
Companies
267
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,872 (81.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,305 (18.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$3,468
2023
$3,022
2022
$687

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$1,525
Janssen Biotech, Inc.
$569
ABBVIE INC.
$529
Boehringer Ingelheim Pharmaceuticals, Inc.
$165
Novartis Pharmaceuticals Corporation
$133
UCB, Inc.
$114
GlaxoSmithKline, LLC.
$100
AstraZeneca Pharmaceuticals LP
$93
PFIZER INC.
$69
Mallinckrodt Hospital Products Inc.
$61
Fresenius Kabi USA, LLC
$33
SOBI, INC
$33
Takeda Pharmaceuticals U.S.A., Inc.
$28
Genentech USA, Inc.
$15
Top 3 companies account for 75.6% of 2024 payments
All-time payments by company (2022-2024) ›
Amgen Inc.
$3,037
Janssen Biotech, Inc.
$1,043
ABBVIE INC.
$829
UCB, Inc.
$390
GlaxoSmithKline, LLC.
$370
Mallinckrodt Hospital Products Inc.
$226
Boehringer Ingelheim Pharmaceuticals, Inc.
$193
Novartis Pharmaceuticals Corporation
$188
PFIZER INC.
$174
Janssen Scientific Affairs, LLC
$150
AstraZeneca Pharmaceuticals LP
$93
Horizon Therapeutics plc
$88
Fresenius Kabi USA, LLC
$66
Lilly USA, LLC
$58
Celltrion USA Inc.
$45
GENZYME CORPORATION
$43
Genentech USA, Inc.
$42
SOBI, INC
$33
Takeda Pharmaceuticals U.S.A., Inc.
$28
Bayer Healthcare Pharmaceuticals Inc.
$28
United Therapeutics Corporation
$27
Lundbeck LLC
$25
Top 3 companies account for 68.4% of all-time payments
Associated products mentioned in payments ›
ACTHAR · Actemra · Adempas · BENLYSTA · Bimzelx · CEREZYME · COSENTYX · Cimzia · EVENITY · Enbrel · HUMIRA · KINERET · KRYSTEXXA · OFEV · Otezla · Prolia · REMICADE · RINVOQ · SIMPONI ARIA · SKYRIZI · TALTZ · TAVNEOS · TEPEZZA · TREMFYA · TYVASO · VPRIV · VYEPTI · XELJANZ · YUFLYMA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (82%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a rheumatology specialist in Los Angeles?
Compare rheumatologists in the Los Angeles area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
193
Per 100K population
2.0
County median income
$87,760
Nearest hospital
CEDAR-SINAI MARINA DEL REY HOSPITAL
3.1 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Peck is a mixed practice specialist, with above-average Medicare volume (top 12% in CA), with low-engagement industry engagement.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Peck experienced with golimumab infusion (simponi aria)?
Based on Medicare claims data, Dr. Peck performed 13,850 golimumab infusion (simponi aria) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Peck receive payments from pharmaceutical companies?
Yes. Dr. Peck received a total of $7,177 from 22 companies across 267 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Peck's costs compare to other rheumatologists in Los Angeles?
Dr. Peck's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Peck) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →